The authors conclude that perilesional administration of HeberFERON (a combination of alpha-2b and gamma interferons) in patients with facial high-risk BCC, offers a satisfactory cure rate after a five-year follow-up with an acceptable safety profile. The gene discussed is IFNG; the disease is skin basal cell carcinoma.